Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Flameret, Inc. Begins Shipping Orders as Initial Order Flow for Cannadol Hemp Oil Exceeds Internal Expectations

FLRE

Company Plans on Introducing Second CBD ("Cannabidiol") Product Within Days Company to Open Amazon Webstore to Further Drive Online Revenues

VENICE, Fla., Sept. 10, 2014 /PRNewswire/ -- Flameret, Inc. (OTC: FLRE) announced today that Royal Hemp Corporation, its wholly-owned Colorado subsidiary, has begun shipping high CBD hemp oil orders. The company previously announced the launch of Cannadol™, its high CBD (cannabidiol) hemp oil. Over the first three days after the product launch was announced, the company received orders from 21 different customers. Further details regarding initial revenues will be announced in the company's financial statements that will be filed at http://www.otcmarkets.com.

Cannadol™ is a dietary supplement sold as a hemp oil rich in CBD. It consists of 200mg of cannabidiol cold pressed from industrial hemp in an oral suspension of 1 ounce of hemp oil. None of the statements regarding Cannadol™ or the potential therapeutic benefits of cannabidiol have been evaluated by the FDA.

Scientific and clinical studies continue to underscore CBD's potential as a possible treatment for a wide range of conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrated neuroprotective and neurogenic capabilities, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere.

John Meredith, Chief Executive Officer of Flameret, Inc. remarked, "The launch of Cannadol™ and the response from consumers has far surpassed our internal expectations. We expect to deliver more good news to the investment public within a week."

Mr. Meredith added, "It is very important as we update investors on our progress that investors also understand that we fully intend on pursuing what we perceive to be a large business opportunity in the flame retardant industry. There seems to be a misconception that we have abandoned that pursuit, however, nothing can be further from the truth. We have recognized an opportunity and we also had confidence that we can get a hemp-based product out on the market quickly. We have done that and our pursuit of a major business opportunity in the flame retardant industry continues."

About Flameret

Flameret, Inc. has developed fire retardant products to suit a wide range of applications. These products are marketed under the brand names; Flameret, Flamex, Ultra Flamex and Impex. Flameret™ products are patented and held in the name of United American Inc.

The company is also in the process of launching a new line of products derived from industrial hemp which will be marketed and sold through Royal Hemp Corporation.

About Royal Hemp Corporation

Royal Hemp Corporation is a Colorado corporation which was created to market and sell hemp-based nutraceuticals, industrial products and consumer goods in the United States and throughout the world. All of the corporation's products will be legal to sell in all states in the United States and in many countries throughout the world.

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's products, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

Contact: John Meredith: jwsmeredith@aol.com
+44 1732 460224

SOURCE Flameret, Inc.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today